Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that ...
Disc Medicine to Participate in Upcoming Investor Conferences - Disc Medicine ( NASDAQ:IRON )
WATERTOWN, Mass., Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that ...
What Makes Disc Medicine, Inc. ( IRON ) a Strong Momentum Stock: Buy Now?
Does Disc Medicine, Inc. (IRON) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Disc Medicine, Inc. ( IRON ) Have the Potential to Rally 26.29% as Wall Street Analysts Expect?
The consensus price target hints at a 26.3% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants - Disc Medicine ( NASDAQ:IRON )
WATERTOWN, Mass., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) ( Disc ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today ...
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ: IRON ) ( Disc ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today ...
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
• Submitted a New Drug Application ( NDA ) for accelerated approval of bitopertin in erythropoietic protoporphyria ( EPP ) on September 29, 2025, and subsequently was awarded the FDA Commissioner's National Priority Voucher ( CNPV ) , a program designed to shorten the expected NDA review period ...
Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings - Disc Medicine ( NASDAQ:IRON ) , Artiva Biotherapeutics ( NASDAQ:ARTV )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Friday. The Dow traded up 0.48% to 46,172.36 while the NASDAQ gained 0.18% to 22,605.82. The S&P 500 also rose, gaining, 0.29% to 6,648.25. Consumer staples shares jumped by 1.2% on Friday.
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday - American Express ( NYSE:AXP ) , AppFolio ( NASDAQ:APPF )
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Friday.
FDA Unveils Fast-Track Drugs to Slash Review Times - Disc Medicine ( NASDAQ:IRON )
The Food and Drug Administration announced on Thursday the first round of experimental drugs to be included in a priority voucher program. This FDA initiative is designed to expedite drug review processes for products that align with critical U.S. national health priorities, reducing review times ...
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease ( CKD ) and Anemia at 2025 American Society of Nephrology ( ASN ) Kidney Week
WATERTOWN, Mass., Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it ...
Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher ( CNPV ) for Bitopertin in Erythropoietic Protoporphyria ( EPP ) - Disc Medicine ( NASDAQ:IRON )
Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPP The CNPV program is designed to reduce the drug application review process to 1-2 months
Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher ( CNPV ) for Bitopertin in Erythropoietic Protoporphyria ( EPP )
WATERTOWN, Mass., Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that ...
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
- Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease ( IBD ) and potentially another autoimmune disease ...
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors - Disc Medicine ( NASDAQ:IRON ) , Shattuck Labs ( NASDAQ:STTK )
- Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease ( IBD ) and potentially another autoimmune disease -
Disc Medicine ( IRON ) Q2 Loss Widens 109%
Disc Medicine ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company advancing treatments for hematologic diseases, released its second quarter 2025 earnings on August 7, 2025. Reflecting investments in critical clinical programs, the period showed progress on pipeline milestones but ...
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
WATERTOWN, Mass., July 14, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the ...
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association ( EHA ) 2025 Congress - Disc Medicine ( NASDAQ:IRON )
Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria ( EPP ) , additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis ( MF ) , and additional data from DISC-3405 studies in ...
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association ( EHA ) 2025 Congress
WATERTOWN, Mass., May 14, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it ...
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
WATERTOWN, Mass., May 07, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported ...
All You Need to Know About Disc Medicine, Inc. ( IRON ) Rating Upgrade to Buy
Disc Medicine, Inc. (IRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. ( IRON ) : Here's What You Should Know
The consensus price target hints at a 68.8% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
WATERTOWN, Mass., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported ...
Disc Medicine, Inc. ( IRON ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants - Disc Medicine ( NASDAQ:IRON )
WATERTOWN, Mass., Jan. 22, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc.
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Jan. 22, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ: IRON ) ( Disc ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today ...
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - AnaptysBio ( NASDAQ:ANAB ) , Associated Cap Gr ( NYSE:AC )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 150 points on Wednesday. Shares of Progress Software Corporation PRGS fell sharply in today's pre-market trading after the company issued first-quarter EPS guidance below estimates.
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria ( EPP ) and Shares Plans for NDA Submission - Disc Medicine ( NASDAQ:IRON )
Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX ( PPIX ) reduction as the surrogate endpoint Planning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON and AURORA Phase 2 trials
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria ( EPP ) and Shares Plans for NDA Submission
WATERTOWN, Mass., Jan. 21, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced ...
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria ( EPP )
WATERTOWN, Mass., Jan. 20, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference ...
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635 ( C ) ( 4 ) - Disc Medicine ( NASDAQ:IRON )
WATERTOWN, Mass., Jan. 17, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. IRON, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the grant of an ...
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635 ( C ) ( 4 )
WATERTOWN, Mass., Jan. 17, 2025 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the ...
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for ...
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology ( ASH ) Annual Meeting - Disc Medicine ( NASDAQ:IRON )
Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indications
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology ( ASH ) Annual Meeting
WATERTOWN, Mass., Dec. 09, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 8 ...
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis ( MF ) and Anemia in an Oral Presentation at the 66th American Society of Hematology ( ASH ) Annual Meeting
WATERTOWN, Mass., Dec. 08, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented ...
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis ( MF ) and Anemia in an Oral Presentation at the 66th American Society of Hematology ( ASH ) Annual Meeting - Disc Medicine ( NASDAQ:IRON )
Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapy Phase 2 study in MF anemia has been initiated, enrolling a broad range of patient types WATERTOWN, Mass., Dec. 08, 2024 ( GLOBE NEWSWIRE ) -- ...
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. - Hercules Capital ( NYSE:HTGC ) , Disc Medicine ( NASDAQ:IRON )
Facility significantly increases future financial and operational flexibility Up to $200M available, with $30 million drawn at close and additional $80 million available at Disc's sole discretion through second-half 2026
Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday - Advance Auto Parts ( NYSE:AAP ) , XIAO-I ( NASDAQ:AIXI )
U.S. stocks were lower, with the Dow Jones index falling around 300 points on Monday. Shares of Integra LifeSciences Holdings Corporation IART rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results.
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria ( EPP ) , Including Potential for Accelerated Approval
WATERTOWN, Mass., Nov. 04, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced ...
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria ( EPP ) - Disc Medicine ( NASDAQ:IRON )
WATERTOWN, Mass., Nov. 01, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. IRON, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to ...
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria ( EPP )
WATERTOWN, Mass., Nov. 01, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference ...
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease ( CKD ) and Anemia at the 2024 American Society of Nephrology ( ASN ) Kidney Week
WATERTOWN, Mass., Oct. 25, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented ...
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease ( CKD ) and Anemia at the 2024 American Society of Nephrology ( ASN ) Kidney Week - Disc Medicine ( NASDAQ:IRON )
WATERTOWN, Mass., Oct. 25, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc.
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease ( CKD ) and Anemia at 2024 American Society of Nephrology ( ASN ) Kidney Week
WATERTOWN, Mass., Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced ...
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer - Disc Medicine ( NASDAQ:IRON )
WATERTOWN, Mass., Sept. 19, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. IRON, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of ...
Stocks Flashing Renewed Technical Strength: Disc Medicine
The Relative Strength ( RS ) Rating for Disc Medicine ( IRON ) jumped into a new percentile Tuesday, with an increase from 75 to 83. ↑ X Do Your Stocks Meet This Key Standard? Here's Why Institutional Support Matters NOW PLAYING Do Your Stocks Meet This Key Standard?
S&P 500 Edges Lower; RH Shares Plunge After Q1 Results - RH ( NYSE:RH )
U.S. stocks traded mixed toward the trading, with the Dow Jones index falling around 0.2% on Friday. The Dow traded down 0.24% to 38,554.69 while the NASDAQ rose 0.07% to 17,680.01. The S&P 500 also fell, dropping, 0.10% to 5,428.33. . Communication services shares jumped by 0.5% on Friday.
Gold Gains 1%; US Consumer Sentiment Falls In June - IN8bio ( NASDAQ:INAB )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Friday. The Dow traded down 0.63% to 38,403.11 while the NASDAQ fell 0.07% to 17,655.10. The S&P 500 also fell, dropping, 0.37% to 5,413.41 . Communication services shares jumped by 0.4% on ...
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday - Hasbro ( NASDAQ:HAS )
U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Friday. Shares of Hasbro, Inc. HAS rose sharply during Friday's session after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $70 to $80. Hasbro shares gained 5.5% to ...
